Source link : https://www.newshealth.biz/health-news/disability-reduction-is-a-twist-in-negative-btki-rrms-trial/
COPENHAGEN — In two phase 3 head-to-head comparing the Bruton tyrosine kinase inhibitor (BTKi) tolebrutinib to the immunomodulatory teriflunomide for relapsing-remitting multiple sclerosis (RRMS), there was no advantage on the primary endpoint of relapse, but the greater protection against disability, a secondary endpoint, might change thinking about BTKis as a potential MS therapy. For annualized […]
Author : News Health
Publish date : 2024-09-24 06:01:54
Copyright for syndicated content belongs to the linked Source.
Categories